Experts detail who can and who should avoid weight loss pens like Ozempic Wegovy Mounjaro

Injectable pens known as slimming pens, based on active ingredients such as semaglutide and tirzepatide, have gained prominence in the treatment of obesity and type 2 diabetes. Especialistas reinforce that use requires a medical prescription and continuous monitoring to ensure safety and effectiveness.

The main indication covers adults with obesity, characterized by a body mass index (BMI) equal to or greater than 30, or overweight (BMI between 27 and 30) associated with comorbidities such as type 2 diabetes, hypertension, dyslipidemia or cardiovascular disease. In specific cases, treatment may include prevention of serious cardiovascular events in patients with a history of heart disease and overweight. Recentemente, regulatory approvals expanded some indications, such as reducing cardiovascular risks with semaglutide in adequate doses.

Patients with type 2 diabetes also benefit from these drugs for glycemic control, especially when other therapies do not achieve satisfactory results. The treatment integrates a low-calorie diet and physical exercise, with average weight losses ranging from 15% to 22% of body weight in clinical studies, depending on the molecule used.

Main indications for using pens

These medications are recommended for chronic treatment of obesity as a disease. Pacientes with high BMI and associated comorbidities present better results when combining medication with lifestyle changes. Endocrinologistas highlight the importance of individualized assessment before prescribing.

Use in adolescents aged 12 and over occurs in specific situations of excess weight with proven clinical need. Acompanhamento multidisciplinary approach becomes essential to monitor progress and adjust doses according to the patient’s response.

Contraindications and risk groups

People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome should not use these drugs due to the potential risk. Hipersensibilidade to any component of the formula represents another absolute contraindication.

Patients with previous or ongoing pancreatitis avoid treatment, as there are reports of worsening pancreatic inflammation. Gestantes, women planning pregnancy or breastfeeding suspend use, with recommendations for prior interruption of at least one to two months depending on the substance.

Risks associated with inappropriate use

Use without a prescription or outside of approved indications increases the chances of serious adverse effects, including acute pancreatitis. X__NM0____

Rapid weight loss without supervision increases the risk of gallbladder stones. Especialistas note that treatment requires regular monitoring of kidney, thyroid and gastrointestinal functions to mitigate complications.

Guidelines from medical societies

Specialized societies recommend prescription only by qualified doctors, with retention of prescription in pharmacies for control. The treatment is not for aesthetic purposes or to lose a few kilos, but rather to manage chronic conditions.

Prior evaluation includes laboratory tests and complete clinical history. Ajustes doses occur gradually to minimize initial gastrointestinal effects such as nausea and vomiting.

Necessary monitoring during treatment

Patients on continuous use undergo regular consultations to assess effectiveness and tolerance. Mudanças in lifestyle, such as a balanced diet and physical activity, complement the medicinal action and help maintain long-term results.

Abrupt interruption may lead to accelerated weight regain. Profissionais guide gradual transition when necessary, always with nutritional and psychological support.

Availability and regulation in Brasil

Medicines such as semaglutide and tirzepatide have health registration and require a double prescription. Versões irregular or manipulated without authorization face prohibitions to protect public health.

Pharmacies retain prescriptions for controlled dispensing. Atualizações regulations aim to expand safe access to eligible patients.